RxSight a new buy at Jefferies on cataract technology

seekingalpha10-30

Toa55/iStock via Getty Images Jefferies has initiated coverage of RxSight (NASDAQ:RXST) at buy citing the company's post-surgical intraocular lenses technology to treat cataracts. The firm has a $72 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479234397?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1868781504/image_1868781504.jpg","is_english":true,"pubTime":"2024-10-30 00:40","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2479234397","market":"sg","top_or_hot":-1,"title":"RxSight a new buy at Jefferies on cataract technology","media":"seekingalpha","content":"<div>\n<p>Toa55/iStock via Getty Images Jefferies has initiated coverage of RxSight (NASDAQ:RXST) at buy citing the company's post-surgical intraocular lenses technology to treat cataracts. The firm has a $72 ...</p>\n\n<a href=\"https://seekingalpha.com/news/4218480-rxsight-new-buy-jefferies-cataract-technology\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RxSight a new buy at Jefferies on cataract technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRxSight a new buy at Jefferies on cataract technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-30 00:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4218480-rxsight-new-buy-jefferies-cataract-technology><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Toa55/iStock via Getty Images Jefferies has initiated coverage of RxSight (NASDAQ:RXST) at buy citing the company's post-surgical intraocular lenses technology to treat cataracts. The firm has a $72 ...</p>\n\n<a href=\"https://seekingalpha.com/news/4218480-rxsight-new-buy-jefferies-cataract-technology\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://seekingalpha.com/news/4218480-rxsight-new-buy-jefferies-cataract-technology","article_id":"2479234397","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1868781504/image_1868781504.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479234397","pubTimestamp":1730220010,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Toa55/iStock via Getty Images Jefferies has initiated coverage of RxSight  at buy citing the company's post-surgical intraocular lenses technology to treat cataracts. The firm has a $72 price target . Analyst Young Li said that RxSight markets the only post-surgery adjustable IOL for cataracts, which differentiates itself from others on the market. As a result, Li sees the company's IOL share in the U.S. going from 10% to at least 50% long term.   A proprietary survey and surgeon checks conducted by Jefferies also indicate that growth will exceed 2025 consensus estimates and EBITDA will turn positive by H2 2026. \"Surveys and recent ECP checks suggests up to ~47% of overall IOL patients are candidates for [RxSight's IOL], with RXST noting ~40% of its patients upgraded from sIOLs,\" Li noted.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","BK4539":"次新股","RXST":"RxSIGHT, INC."},"translate_title":"RxSight是Jefferies对白内障技术的新收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXST":0.9},"content_text":"Toa55/iStock via Getty Images Jefferies has initiated coverage of RxSight (NASDAQ:RXST) at buy citing the company's post-surgical intraocular lenses technology to treat cataracts. The firm has a $72 price target (~43% upside based on Oct. 28 close). Analyst Young Li said that RxSight markets the only post-surgery adjustable IOL for cataracts, which differentiates itself from others on the market. As a result, Li sees the company's IOL share in the U.S. going from 10% to at least 50% long term.   A proprietary survey and surgeon checks conducted by Jefferies also indicate that growth will exceed 2025 consensus estimates and EBITDA will turn positive by H2 2026. \"Surveys and recent ECP checks suggests up to ~47% of overall IOL patients are candidates for [RxSight's IOL], with RXST noting ~40% of its patients upgraded from sIOLs,\" Li noted.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479234397"}